Release Date: 22-Oct-2024
Antibody drug conjugates (ADCs) are emerging as a promising approach in the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC). Currently, there is only one approved ADC for lung cancer, with two others under review, reflecting the dynamic nature of this field. The first ADC to gain approval specifically for lung cancer was Enhertu (trastuzumab deruxtecan), which initially received its approval in 2019 for breast cancer but was authorized for patients with HER2-mutant metastatic NSCLC in 2022. This marked a significant milestone as it became the first HER2-directed therapy for patients who had already undergone prior treatments. The accelerated approval of Enhertu was based on the promising results from the DESTINY-Lung02 Phase II trial, which demonstrated substantial efficacy in this challenging patient population.
“Currently More Than 60 Antibody Drug Conjugates Are Under Clinical Investigation Across Multiple Phases For Lung Cancer Say Neeraj Chawla, Research Head At Kuick Research”
Download Insight: https://www.kuickresearch.com/report-cancer-drug-conjugates-market-size
In addition to Enhertu, datopotamab deruxtecan is currently under review for the treatment of adults with locally advanced or metastatic nonsquamous NSCLC who have received prior systemic therapy. This ADC, developed by AstraZeneca and Daiichi Sankyo, is positioned to address a critical need for more effective therapies in lung cancer. The FDA is expected to make a regulatory decision regarding datopotamab deruxtecan in the fourth quarter of 2024, raising anticipation among patients and healthcare providers alike.
The landscape for ADCs in lung cancer is expanding rapidly, with over 60 ADCs currently in clinical trials, signaling a robust pipeline that could reshape the treatment paradigm. Among the notable late-stage candidates are Sacituzumab tirumotecan by Merck, which targets TROP2, Sigvotatug vedotin from Pfizer, targeting integrin beta-6, and Ifinatamab deruxtecan from Daiichi Sankyo, which targets B7-H3. Each of these ADCs is designed to target specific markers critical to the progression of lung cancer, aiming to improve efficacy and reduce toxicity compared to traditional chemotherapy.
The potential of ADCs to revolutionize the treatment landscape for lung cancer cannot be overstated. By combining targeted therapy with cytotoxic agents, ADCs offer a more precise treatment option that could lead to improved outcomes for patients who have limited choices after standard therapies. This innovation aligns with the ongoing shift in cancer treatment toward personalized medicine, where therapies are tailored to the specific genetic and molecular characteristics of a patient's tumor.
As research and clinical trials continue to progress, the expectation is that more ADCs will gain approval, providing new hope for patients battling lung cancer. With continued advancements in this field, the future may hold significantly improved treatment options that enhance survival rates and quality of life for those affected by this disease.